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Familial Syndromes of Primary 
Hyperparathyroidism
William F. Simonds
Abstract
Regulation of serum calcium in vertebrates is maintained by the actions of the 
parathyroid glands working in concert with vitamin D and critical target tissues that 
include the renal tubules, the small intestine, and bone cells. The parathyroid glands 
release parathyroid hormone (PTH) into the systemic circulation as is required in 
order to maintain the serum calcium concentration within a narrow physiologic 
range. Excessive secretion of PTH from one or more abnormal parathyroid glands 
however results in primary hyperparathyroidism (HPT), a metabolic disease typi-
cally associated with abnormally elevated serum calcium. Although HPT is typically 
a sporadic disease, it can represent a manifestation of an inherited syndrome. Many 
sporadic parathyroid tumors result from inactivating mutations in tumor suppres-
sor genes that were first discovered by the analysis of genomic DNA from patients 
with HPT as part of an inherited syndrome. Somatic and inherited alterations in 
DNA encoding proto-oncogenes can also cause parathyroid neoplasia. Two promis-
ing future approaches for the discovery of novel genes pertinent to parathyroid 
tumor development are the analysis of acquired genetic alterations in DNA isolated 
from parathyroid tumors and the investigation of familial HPT in kindreds lacking 
germline mutation in the known genes predisposing to HPT.
Keywords: multiple endocrine neoplasia, MEN1, MEN2A, jaw tumor syndrome, 
CDC73, HRPT2, GCM2, CCND1, RET, CASR, CDKN1B, tumor suppressor, oncogene
1. Introduction
The inappropriate or excessive secretion of parathyroid hormone (PTH) from 
one or multiple abnormal parathyroid glands typically results in hypercalcemia and 
the disorder of mineral metabolism called primary hyperparathyroidism (HPT) 
[1]. Most cases of HPT are sporadic (~95%). Among the small remaining fraction 
of patients with an inherited basis for HPT, most harbor germline mutation of a 
known parathyroid tumor susceptibility gene (listed in Table 1). In spite of their 
infrequency, study of the genetics of these uncommon inherited syndromes has 
yielded substantial insight into the etiology of both sporadic and familial parathy-
roid tumor development. Since the release of PTH from parathyroid cells involves 
close regulation by the calcium-sensing receptor (CASR), a cell surface transmem-
brane receptor of the G protein-coupled receptor family C [2], the germline muta-
tion of the CASR and other genes mediating its signaling can also result in inherited 
syndromes characterized by hypercalcemia and circulating levels of PTH that are 
elevated or inappropriately normal. This chapter will summarize current knowledge 
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Gene Corresponding 
protein
Chromosomal 
location
Associated 
hyperparathyroid 
syndrome: main 
syndromic 
manifestations
Features of 
syndromic 
parathyroid 
tumors
MEN1 Menin 11q13.1 Multiple endocrine 
neoplasia type 1 
(MEN1): anterior 
pituitary, parathyroid, 
enteropancreatic, 
foregut carcinoid 
tumors
Multiple, 
asymmetric tumors 
typical (>99% 
benign)
CDC73/
HRPT2
Parafibromin 1q31.2 Hyperparathyroidism-
jaw tumor syndrome: 
fibro-osseous jaw, 
parathyroid, uterine 
tumors; renal cysts
Single tumor 
common (~20% 
malignant)
CDKN1B P27(Kip1) 12p13.1 Multiple endocrine 
neoplasia type 4 
(MEN4): anterior 
pituitary, other 
involvement varies
Single to multiple 
glands (benign in 
reports to date); 
can be recurrent
GCM2 Glial cells missing 
transcription 
factor 2
6p24.2 Familial isolated 
primary 
hyperparathyroidism
Single to multiple 
glands
CASR Calcium-sensing 
receptor
3q13.33-q21.1 Familial hypocalciuric 
hypercalcemia 
type 1 (FHH1) 
with heterozygous 
inactivation; 
neonatal severe 
hyperparathyroidism 
(NSHPT) with 
homozygous 
inactivation
FHH1: near-normal 
size and surgical 
pathology; altered 
serum calcium 
set-point for PTH 
release
NSHPT: marked 
enlargement of 
multiple glands 
by polyclonal 
(non-neoplastic) 
mechanism
GNA11 G protein α11 
subunit
19p13.3 Familial hypocalciuric 
hypercalcemia type 2 
(FHH2)
ND
AP2S1 Adaptor 
protein-2 sigma 
subunit
19q13.32 Familial hypocalciuric 
hypercalcemia 
type 3 (FHH3): 
hypercalcemia more 
severe than in FHH1
ND
RET c-Ret 10q11.21 Multiple endocrine 
neoplasia type 
2A: medullary 
thyroid cancer, 
pheochromocytoma, 
parathyroid tumors
Single tumor 
common (>99% 
benign)
CCND1/
PRAD1
Cyclin D1 11q13.3 NA (to date, only 
implicated in sporadic 
parathyroid tumors)
NA (to date, 
only implicated 
in sporadic 
parathyroid 
tumors)
Table 1. 
Genes implicated in syndromic parathyroid neoplasia and related hypercalcemic states.
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of the clinical genetics and molecular pathophysiology of HPT that results from 
both benign and malignant parathyroid gland neoplasia.
2. The evolution of calcium regulation in vertebrates
In sea water the concentration of elemental calcium is approximately 10 mM. As 
a result, early eukaryotes living in a marine environment had easy access to cal-
cium. Given this abundant supply of extracellular calcium, numerous intracellular 
processes evolved in simple eukaryotes that depended on this divalent cation. Such 
calcium-dependent processes were preserved in metazoans. Thus marine chor-
dates and early vertebrate fish depended on calcium for cellular processes such as 
membrane permeability, neurotransmitter release, intracellular second messenger 
signaling, muscular contraction, neuromuscular excitability, and the actions of 
multiple calcium-dependent enzymes. Calcium’s particular coordination chemistry 
facilitated many proteins’ ability to reversibly bind divalent calcium ions, thus 
enabling signaling through such binding [3].
Calcium is much scarcer on land compared to the marine environment. As lobe-
finned fish, marine vertebrates believed to be the ancestors of the early amphibians, 
began to explore the periphery of the terrestrial environment, evolutionary pres-
sure to develop a system of internal calcium balance mounted. A system of internal 
calcium homeostasis at the organismal level would ensure the continued preserva-
tion and function of numerous cellular and tissue operations that vitally depended 
on calcium.
Metabolically-active trabecular or cancellous bone in lobe-finned fish and 
associated hematopoietic bone marrow likely co-evolved [4]. These developments 
probably both lightened overall skeletal mass and provided a reliable internal source 
of calcium as a basis for calcium homeostasis. The lightening of skeletal mass was 
critical since lobe-finned fish and early amphibians had to come to terms with full 
gravitational force in their terrestrial movements, no longer buoyed by surrounding 
seawater in accordance with Archimedes’ principle [5]. The potential significance 
of the close physical apposition of hematopoietic bone marrow to spongiform bone, 
inferred from X-ray synchrotron microtomography of fossilized lobe-finned fish 
humerus [4], is suggested by the realization that osteoclasts, cells uniquely special-
ized to mobilize ionized calcium via resorption of bone, develop from hemato-
poietic stem cell precursors [6]. In contrast, osteoblasts, which lay down osteoid 
and mineralize bone, derive from mesenchymal stem cells which are abundant in 
non-hematopoietic bone marrow.
Although analogs of Gcm2, Gata3, CaSR, PTH, and other genes associated with 
the development and function of human parathyroid glands are expressed in the 
fish gills, actual parathyroid glands are first seen in amphibians [7–9]. Complete 
surgical excision of parathyroid gland tissue in amphibians, reptiles, birds, and 
mammals results in tetany and death.
3. The pathophysiology of primary hyperparathyroidism
PTH secretion from cells of the parathyroid glands is finely regulated in 
response to changes in the ambient ionized calcium level in order to maintain 
the circulating calcium concentration within a defined physiologic range. The 
G protein-coupled CASR is a critical regulator of PTH secretion and is located 
on the plasma membrane of chief cells in the parathyroid glands [10, 11]. In 
a classic endocrine negative feedback loop, the active form of cholecalciferol, 
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1,25-dihydroxyvitamin D, whose synthesis is stimulated by PTH acting on proxi-
mal renal tubular cells, inhibits PTH biosynthesis and release from parathyroid 
cells [12–15]. The simultaneous demonstration of elevated serum calcium with an 
inappropriately normal or elevated PTH is a typical clinical definition of HPT [16]. 
The vast majority of parathyroid tumors are adenomas (i.e. benign tumors), with 
parathyroid cancer accounting for less than 1% of HPT in most series.
Most cases of HPT are sporadic with inherited forms of HPT representing only 
2–5% of cases. As illustrated in Table 1, research into the molecular pathophysiol-
ogy of this small subcategory of cases has notwithstanding yielded important 
understanding with respect to the genes and pathways that promote parathyroid 
tumorigenesis. Multiple endocrine neoplasia type 1 (MEN1), multiple endocrine 
neoplasia type 2A (MEN2A), the hyperparathyroidism-jaw tumor syndrome 
(HPT-JT), and familial isolated hyperparathyroidism (FIHP) are the most common 
inherited disorders associated with HPT [17–21]. Familial hypocalciuric hypercal-
cemia (FHH) is a related and largely benign autosomal dominant condition char-
acterized by lifelong asymptomatic hypercalcemia. Often mis-diagnosed as HPT, 
in FHH the PTH-dependent hypercalcemia does not correct with partial or even 
subtotal parathyroidectomy [22]. The relevance of these inherited disorders to the 
underlying molecular pathogenetic alterations in parathyroid tumorigenesis will be 
discussed in more detail below.
4. Oncogenes and proto-oncogenes
Mutant genes that drive cell growth are called oncogenes and represent one 
potential molecular mechanism for tumor development. Oncogenes are mutation-
ally activated versions of naturally occurring genes, called proto-oncogenes, which 
under normal conditions positively regulate cell division and/or cell growth [23]. 
Oncogenes represent gain-of-function mutants or overexpressed forms of proto-
oncogenes that can induce cell growth and cell division, often in a tissue-specific 
fashion, resulting in tumor formation. Proto-oncogenes often encode proteins 
that are involved in mitogenic signal transduction. In the context of currently 
recognized familial cancer syndromes, germline mutational activation of proto-
oncogenes is rare as an etiology compared to the inactivation of tumor suppressor 
genes (see below). Constitutive proliferative signaling resulting from the germline 
activation of most proto-oncogenes would presumably be deleterious to embryonic 
and fetal development.
5. The role of tumor suppressor genes in tumor development
Alfred Knudson proposed another model for tumor development based on the 
study of retinoblastoma disease patterns nearly 50 years ago [24]. Sporadic reti-
noblastoma is usually monocular. Familial retinoblastoma, though rare compared 
to the sporadic form, is more frequently binocular and has a much earlier age of 
onset. The “two-hit” hypothesis of tumor development, as proposed by Knudson, 
hypothesizes that two events (or “hits”) in a parental cell confer a selective growth 
advantage and result in that cell’s clonal expansion [25].
Newer clinical and molecular genetic insight that has emerged since his origi-
nal proposal allow us to update Knudson’s concept. In many hereditary tumor 
syndromes, an inherited germline DNA mutation that affects one copy of a tumor 
suppressor gene represents the first “hit” or event and is present throughout all cells 
of the affected offspring. The greater likelihood of any particular cell acquiring a 
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“second hit”, i.e. a somatic mutation in the second allele of the same tumor suppres-
sor gene that was heretofore unaffected, accounts for the earlier age of onset and 
predisposition for bilateral and multifocal disease in hereditary tumor syndromes. 
This “second hit” in somatic DNA, that disables the remaining wild-type allele, 
typically results from a deletion that involves a portion or the entirety of a chromo-
some. In the familial tumor syndromes MEN1 and HPT-JT, inactivating mutation 
that involves both alleles of the MEN1 and the CDC73/HRPT2 tumor suppressor 
genes, respectively, can often be found in parathyroid tumor-derived DNA. In such 
patients, the first “hit”, namely a loss-of-function mutation of the relevant tumor 
suppressor gene, can frequently be demonstrated in the germline DNA.
6. Multiple endocrine neoplasia type 1 (MEN1)
MEN1 is the most common hereditary cause of primary hyperparathyroidism 
[26]. The syndrome of MEN1 is characterized by the predisposition to develop 
tumors derived from cells in the anterior pituitary, parathyroid glands, and 
endocrine cells present in the gut and pancreatic islets (such as gastrinomas, and 
pancreatic neuroendocrine tumors such as insulinomas) [27]. Tumors in several 
other endocrine organs and non-endocrine tumors such as lipomas, angiofibromas, 
and leiomyomas affecting the esophagus, uterus, and/or ureters for example, can 
also be associated with the syndrome [27]. HPT is the most penetrant hormonal 
feature of MEN1.
Familial MEN1 is characterized by autosomal dominant transmission. The pre-
disposition to tumor development in one of the tissues characteristically involved 
in the MEN1 syndrome is caused by germline inactivating mutation in one copy of 
the MEN1 gene on chromosome 11q13 [28]. As of 2015, 576 unique germline muta-
tions in MEN1 were reported from patients and families with MEN1 [29]. The study 
of DNA derived from pituitary, parathyroid, and entero-pancreatic tumors from 
MEN1 patients has shown that most syndromic tumors possess an acquired dele-
tion or other inactivating mutation of the second, wild-type MEN1 allele [18, 30]. 
Approximately 10% of patients with MEN1 on a clinical basis are germline MEN1 
mutation-negative.
Conventional DNA sequencing of tumor DNA has identified somatic MEN1 
mutation in up to 35% of sporadic parathyroid adenomas [31–35]. In studies testing 
for loss-of-heterozygosity (LOH) in sporadic parathyroid adenomas, the frequency 
of LOH at the MEN1 locus on chromosome 11q13 ranged from 26 to 37%. Using 
whole exome sequencing (WES) methodology, somatic MEN1 mutation was 
found in some 35% of parathyroid benign tumors, comparable to results using 
conventional Sanger DNA sequencing [36, 37]. As mentioned above, HPT is the 
most penetrant feature of MEN1 and is usually the initial manifestation. As a result, 
true MEN1 families may sometimes be initially mis-assigned a clinical diagnosis of 
familial isolated hyperparathyroidism (FIHP) if only younger affected members are 
considered at the time that the family is ascertained (see Figure 1).
Mutation of the MEN1 gene is only rarely associated with parathyroid carci-
noma. The occurrence of parathyroid carcinoma in the context of familial MEN1 is 
extremely uncommon. Fewer than 20 patients with HPT due to parathyroid cancer 
in the context of the MEN1 syndrome have been reported [38]. LOH analysis of 
parathyroid tumor-extracted DNA has shown that DNA loss at the location of the 
MEN1 gene on chromosome 11q, though frequently seen in benign parathyroid 
tumors, is quite uncommon in parathyroid carcinomas [39]. Recent studies that use 
next-generation WES of tumor-derived DNA to profile parathyroid cancers did not 
report any somatic mutations in MEN1 [40, 41].
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7. The hyperparathyroidism-jaw tumor syndrome (HPT-JT)
HPT-JT is a familial syndrome with variable and incomplete penetrance trans-
mitted in an autosomal dominant fashion. The key clinical features of HPT-JT 
include HPT, jaw tumors (fibro-osseous tumors involving the maxilla and/or man-
dible, formally classified as cemento-ossifying fibromas [42], and distinct from so 
called “brown” tumors sometimes associated with HPT), renal cysts or tumors and 
uterine tumors in women [43–45]. HPT is the most penetrant feature of HPT-JT and 
is usually the presenting manifestation. In contrast to MEN1, parathyroid cancer is 
frequent in HPT-JT, affecting some 20% or more of those with HPT [43–46].
In the majority of HPT-JT kindreds, a germline loss-of-function mutation of 
the CDC73 gene (formerly called HRPT2) can be identified [19, 47]. The majority 
of such CDC73 mutations are predicted to inactivate gene function via frameshift 
or nonsense mutation, and only a minority of the mutations are missense [48]. 
Patients and kindreds with partial or complete deletion of the CDC73 gene in the 
germline have also been described [49–52]. The CDC73 gene encodes a 531-residue 
protein named parafibromin [47]. Because germline mutation predicted to cause 
loss-of-function of the CDC73 gene predisposes to the neoplastic expressions 
Figure 1. 
The relationship among familial forms of hyperparathyroidism that may present as familial isolated 
hyperparathyroidism (FIHP) as a Venn diagram. The dashed circle represents the set of patients that can 
present with a provisional diagnosis of FIHP at the time of initial ascertainment. This includes patients with 
FIHP who have been evaluated for, but lack findings diagnostic of, MEN1, FHH and HPT-JT (nonsyndromic 
FIHP; in a solid circle). Approximately 18% of nonsyndromic FIHP kindreds harbor germline gain-of-function 
mutations in GCM2 (see text), whereas the remainder have currently unknown genetic etiologies. Subsets of 
patients with incomplete expression of MEN1, FHH and HPT-JT (the total set of patients in each syndrome 
represented by a solid circle) can also present with the FIHP phenotype (and thus overlap with the dashed 
circle). The distinction between the nonsyndromic FIHP category and the syndromic categories arbitrarily 
depends on the thoroughness of evaluation and the sensitivity of diagnostic tests used to detect the syndrome that 
can include germline gene mutational testing. MEN2A is a familial form of hyperparathyroidism that seldom 
if ever presents as FIHP. Within each circle representing a defined syndrome are included the genetic locus (or 
loci in the case of FHH; see text) of the syndromic trait and the associated gene product. The causative gene for 
HPT-JT encoding parafibromin is CDC73, formerly called HRPT2. The relationship among the patient sets 
illustrated as circles in this diagram is intended to be qualitative and neither the area of each circle nor the area 
of overlap between circles has any quantitative significance.
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of HPT-JT, parafibromin is considered to be a tumor suppressor protein. Mixed 
epithelial tumor of the kidney (MEST), a rare type of renal tumor (formerly clas-
sified as cystic hamartoma of the renal pelvis, leiomyomatous renal hamartoma, or 
adult type mesoblastic nephroma), has been associated with HPT-JT and appears 
to correlate with a specific CDC73 genotype, namely the Met1ILe missense muta-
tion replacing the initiator methionine of parafibromin with isoleucine [47, 53, 54]. 
Somatic mutation of the CDC73 tumor suppressor gene is uncommon in sporadic 
parathyroid adenomas [55]. In contrast to the results of analyses in benign parathy-
roid tumors, mutations of CDC73 are quite frequently seen in apparently sporadic 
cases of parathyroid cancer [56–58]. Interestingly, recurrent somatic mutations in 
CDC73 have been documented by exome sequence analysis of tumor DNA from 
parathyroid cancers [40, 41]. Selective amplification of the mutant copy of CDC73 
has been demonstrated in a subset of parathyroid carcinomas [40]. Approximately 
25% of cases of seemingly sporadic parathyroid carcinoma may possess germline 
loss-of-function alterations in CDC73, suggesting that such patients may in fact 
have previously unrecognized, or formes frustes of, HPT-JT [19, 57, 58]. A minority of 
patients and families classified as FIHP can be shown to carry CDC73 mutation in 
the germline, suggesting that this inherited disorder may in some cases be pheno-
copied by incompletely penetrant HPT-JT (see below and Figure 1). Approximately 
20% of genetically confirmed or obligate CDC73 mutation-positive family members 
lack HPT, fibro-osseous jaw tumors, or other manifestations of HPT-JT when their 
kindred is initially ascertained. Because the penetrance of the manifestations of 
HPT-JT increases with age among CDC73 mutation carriers, lifelong surveillance of 
initially asymptomatic carriers is recommended [59].
8. Multiple endocrine neoplasia type 4 (MEN4)
MEN4 is a syndrome originally described by Pellegata and coworkers in a multi-
generational family with features resembling MEN1, including a proband with a 
growth hormone-secreting pituitary adenoma and HPT, but lacking germline MEN1 
mutation [60, 61]. A germline heterozygous truncation mutation in CDKN1B was 
identified in the proband and several members of this kindred [60]. CDKN1B encodes 
the cyclin dependent-kinase inhibitor p27 (Kip1). Attention to the CDKN1B locus 
was a consequence of a previous genetic analysis of rats with the MenX phenotype, a 
recessively inherited condition caused by a frameshift mutation in Cdkn1b [60, 62]. 
The MenX phenotype in rats was manifest by the development of bilateral pheochro-
mocytomas, paragangliomas, parathyroid adenomas and thyroid C cell hyperplasia 
[60, 62]. In the study by Pellegata et al., the proband was the only member of the 
MEN4/MENX kindred described who manifested HPT [60].
Following the original report by Pellegata et al. [60], several groups have inves-
tigated a possible role for CDKN1B mutation in parathyroid tumorigenesis. None of 
the earlier reports of MEN1 mutation-negative families harboring germline muta-
tion in CDKN1B, and expressing MEN1-like tumors and thus classified as MEN4, 
had included families with more than one member with HPT proven to track with 
the CDKN1B mutation [60, 63–71], apart from the demonstration of HPT linked 
to CDKN1B mutation in monozygotic twins [64]. That was true until a more recent 
report by Frederiksen et al. describing a large Danish family in which HPT occurred 
in 13 members, spanning two generations, who carried a germline frameshift 
CDKN1B mutation [72].
Recent evidence supports the characterization of CDKN1B as a susceptibility 
gene for the development of primary parathyroid tumors [69, 72, 73]. This evidence 
validates the inclusion of germline CDKN1B mutation in the differential diagnosis 
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of familial HPT, particularly in the evaluation of germline MEN1 mutation-negative 
families who yet have MEN1-like features. The strongest justification for this follows 
from consideration of the Danish kindred in which 13 unique family members 
manifest HPT linked to germline inactivating mutation of CDKN1B, described by 
Frederiksen and co-workers [72].
9. Familial isolated hyperparathyroidism (FIHP)
By definition, FIHP is a non-syndromic category of familial HPT describing 
families that contain two or more members with HPT but which lack the specific 
features of MEN1, MEN2A, HPT-JT or FHH (Figure 1) [74]. FIHP is genetically 
heterogeneous and is a diagnosis of exclusion. While at the time of initial ascertain-
ment germline mutation of MEN1, CDC73, or CASR may account for a fraction of 
kindreds with the FIHP phenotype [20, 34, 75–77], the majority of FIHP families 
lack mutations in these established HPT-susceptibility genes (Figure 1) [20, 75, 78].
Missense variants in GCM2, a transcription factor homologous to the Drosophila 
“glial cells missing” (gcm) gene and required for parathyroid gland development, 
were recently described in the germline DNA of eight unrelated families with FIHP 
[21]. Previous studies showed that germline dominant-negative and loss-of-func-
tion mutations in GCM2 were associated with autosomal dominant and autosomal 
recessive familial isolated hypoparathyroidism, respectively [79, 80]. The two rare 
germline GCM2 genetic variants associated with FIHP act as gain-of-function 
mutations [21]. These missense mutations map to the C-terminal conserved 
inhibitory domain (CCID) of GCM2 and increase its transcriptional activity when 
measured in vitro, suggesting that GCM2 in the context of FIHP is a parathyroid 
proto-oncogene. It has been estimated that approximately 18% of FIHP families 
harbor germline activating GCM2 mutations [21], leaving ~80% of FIHP families 
without a currently-identified genetic etiology [74]. Other clinical investigators 
have identified rare germline GCM2 variants in a subset of FIHP kindreds [81]. 
Activating GCM2 variants mapping to the CCID region have been found among 
patients with sporadic parathyroid tumors in low frequency and appear to be of low 
penetrance [82].
10. Familial hypocalciuric hypercalcemia (FHH)
FHH is a condition of PTH-dependent hypercalcemia, often resembling HPT, 
that is clinically benign and genetically heterogeneous (Table 1) [22]. Following 
partial or subtotal parathyroidectomy, affected patients from FHH kindreds almost 
always remain hypercalcemic. FHH is transmitted in an autosomal dominant 
fashion and usually causes mild hypercalcemia with relative hypocalciuria. The 
hypercalcemia seen in FHH is highly penetrant across all ages, including in infants 
[22, 83]. The majority of cases of FHH result from heterozygous germline inactivat-
ing mutation of the CASR gene on the long arm of chromosome 3 that encodes the 
calcium-sensing receptor [10, 84], and is classified as type 1 FHH (FHH1). Neonatal 
severe hyperparathyroidism (NSHPT), a rare autosomal recessive disorder typically 
presenting with severe hypercalcemia occurring in the first 6 months of life, most 
often results from the compound heterozygous or homozygous inheritance of two 
loss-of-function mutant CASR alleles [85]. Rather than the cellular monoclonality 
that would be expected in true parathyroid tumors, molecular genetic analysis of 
the hyperfunctioning parathyroid glands removed from a patient with NSHPT 
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demonstrated generalized polyclonal hyperplasia, underscoring the non-neoplastic 
nature of the abnormal parathyroid glands associated with CASR inactivating 
mutation [86].
Loss of surface expression of the CASR protein has been documented in 
parathyroid adenomas and may contribute to the altered calcium set point and 
impaired calcium-mediated negative feedback on the release of PTH typical of 
such adenomas. Decreased CASR mRNA expression, but not LOH at the CASR 
locus, has been documented in parathyroid adenomas [87]. In sporadic parathy-
roid tumors studied to date, somatic inactivation of the CASR gene has not been 
reported [88, 89].
Type 2 FHH (FHH2) resulting from germline loss-of-function mutation of 
GNA11, encoding the G protein α11 subunit [90, 91], and type 3 FHH (FHH3) 
resulting from germline inactivating mutation in AP2S1, the gene that encodes an 
adaptor protein involved in endocytosis mediated by clathrin [92–95], have also 
been described. In studies of sporadic parathyroid tumors, somatic inactivating 
mutations of GNA11 and AP2S1 have so far not been reported.
11. Multiple endocrine neoplasia type 2A (MEN2A)
MEN2A is a familial cancer syndrome characterized by a predisposition to the 
development of medullary thyroid cancer (MTC), pheochromocytoma (typically 
benign and often bilateral), and primary HPT. In the context of MEN2A, HPT is 
usually mild and resembles sporadic HPT. HPT in MEN2A is almost always results 
from benign parathyroid disease. MEN2A is an autosomal dominant disorder that 
results from germline gain-of-function mutation in the RET proto-oncogene at 
chromosomal location 10q11. RET encodes a receptor tyrosine kinase that binds the 
ligand glial derived neurotrophic factor, together with a glycosylphosphatidylinosi-
tol-anchored protein co-receptor Gfra1 [96].
Germline oncogenic mutations of RET are associated with three distinct familial 
endocrine neoplasia syndromes, all associated with MTC: MEN2A, multiple endo-
crine neoplasia type 2B (MEN2B), and familial medullary thyroid cancer (FMTC). 
The disease spectrum of typical MEN2B or FMTC does not include parathyroid 
tumors and HPT. Genotype–phenotype correlations based on particular RET 
mutations are apparent and account for the distinct patterns of disease. Some 95% 
of MEN2A cases are due to the presence in the germline of nonsynonymous variants 
affecting the RET receptor’s extracellular cysteine-rich domain, namely missense 
mutations of RET codons 609, 611, 618, 620, or 634 [97]. In fact, germline missense 
alteration of RET residue cysteine-634 accounts for approximately 85% of cases of 
MEN2A [98].
12. Parathyroid tumorigenesis involving the CCND1 oncogene
The discovery of the CCND1 (or PRAD1, for parathyroid adenomatosis 1) 
oncogene resulted from the analysis of several large, non-familial, parathyroid 
adenomas that harbored DNA re-arrangements that involved the PTH gene locus 
[99–101]. A breakpoint resulting from the pericentromeric inversion of chromo-
some 11 DNA was identified just upstream of the CCND1/PRAD1 oncogene [101]. 
The inversion positioned the PTH gene regulatory region, that is normally located 
on the short arm of chromosome 11, just upstream of the CCND1/PRAD1 proto-
oncogene located on 11q [99–101]. The product encoded by the proto-oncogene 
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was subsequently recognized by DNA sequence analysis to be a member of the 
cyclin protein family [101]. The gene was therefore re-named cyclin D1 (CCND1). 
Overexpression of CCND1 in the parathyroid cells of transgenic mice induces cell 
proliferation and gives rise to the metabolic abnormalities that characterize HPT 
in humans [102].
While activating CCND1 missense mutations have not been observed in sporadic 
parathyroid tumors [103], overexpression of CCND1 has been demonstrated in 
20–40% of sporadic benign parathyroid tumors and in an even larger percentage of 
parathyroid carcinomas [104–107]. In parathyroid carcinoma, no somatic chromo-
somal rearrangements on chromosome 11 involving CCND1 have been reported. 
Neither germline activating missense mutations of CCND1 nor chromosomal 
translocations or rearrangements involving the CCND1 locus have been reported in 
any familial form of HPT.
13. Other genes involved in parathyroid tumorigenesis
Recurrent mutations in a subset of genes likely relevant to parathyroid tumori-
genesis have been identified by WES analysis of DNA derived from sporadic 
parathyroid tumors. Eight out of 193 sporadic parathyroid tumors analyzed by 
WES demonstrated the Y641N missense mutation in the EZH2 gene on chromo-
some 7 that encodes the enhancer of zeste 2 polycomb repressive complex 2 subunit 
[36]. Analysis by WES of 22 parathyroid tumors derived from a Chinese patient 
population identified a distinct somatic missense mutation, Y646N, in EZH2 
[108]. Acquired mutations of Y641 and Y646 in EZH2 were described previously in 
lymphoid malignancy [109, 110]. Molecular genetic profiling of 80 sporadic para-
thyroid neoplasms by separate investigators failed to uncover any pathogenic EZH2 
mutations however, suggesting acquired EZH2 mutation may be uncommon in 
parathyroid tumors [111]. In the context of lymphoma, EZH2 is thought to function 
as a proto-oncogene [109]. To date, no transgenic mouse models restricting EZH2 
mutation or overexpression to parathyroid cells have been reported.
Soong and Arnold used WES analysis of DNA extracted from 19 parathyroid 
adenomas and matching germline DNA to identify somatic mutations in ZFX, a 
putative parathyroid proto-oncogene and member of the Krüppel associated box 
domain-containing family of zinc finger protein transcription factors [112]. Their 
observations in the discovery cohort were confirmed by direct sequencing of tumor 
DNA from an additional validation set comprised of 111 parathyroid adenomas 
[112]. The mutant ZFX alleles detected in parathyroid tumors likely act as onco-
genes [113]. Such somatically acquired ZFX mutations in parathyroid tumors may 
be uncommon, however, since an independent mutational analysis of 23 sporadic 
parathyroid carcinomas and 57 adenomas failed to identify any pathogenic ZFX 
variants [111]. The development of a transgenic mouse model and/or better char-
acterization of the functional properties of the mutant ZFX protein may clarify the 
potential significance of ZFX as a parathyroid proto-oncogene.
WES analysis of 22 blood-sporadic parathyroid adenoma tumor pairs from a 
Chinese patient cohort identified recurrent mutations of ASXL3 [108]. ASXL3 
belongs to a family of vertebrate Additional sex combs (Asx)-like proteins that 
may function as regulators of transcription. It remains unclear if the somatic 
missense ASXL3 mutations identified in the parathyroid adenomas, mutations that 
affected highly conserved residues, would result in gain- or loss of ASXL3 function 
[108]. Further studies will be required to confirm this initial observation and to 
clarify the mechanism by which ASXL3 mutation might drive parathyroid tumor 
development.
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14. Conclusions
While inherited forms of HPT represent only a small fraction of cases (<5%), 
study of the molecular pathophysiology of these uncommon familial syndromes has 
yielded substantial insight into the genetic etiology of both sporadic and familial 
parathyroid disease and resulted in the identification of genes such as MEN1, 
CDC73, CASR, GNA11, AP2S1, CDKN1B, CCND1, and GCM2. It is highly likely 
that the mutational gain- or loss-of-function of other, yet unrecognized, genes is 
able to drive parathyroid neoplasia. For example, the risk in the majority of FIHP 
kindreds predisposing to the development of parathyroid tumors seems to result 
from the germline mutation of genes not presently recognized as having a role in 
parathyroid disease. This follows from the observation that nearly 70% of families 
initially considered as FIHP in multiple studies that examined for germline MEN1, 
CASR and CDC73/HRPT2 gene mutation, had no recognized syndromic etiology 
(Figure 1) [20, 75–77]. From among those FIHP kindreds who are MEN1, CASR 
and CDC73 mutation-negative, only about 20% are estimated to harbor germline 
activating mutations in the GCM2 proto-oncogene [21], which leaves nearly 80% of 
FIHP kindreds with a currently-undefined genetic basis for their disease (Figure 1).
The existence of currently unidentified parathyroid tumor suppressors and 
oncogenes is also suggested by analysis of parathyroid tumors using techniques such 
as comparative genomic hybridization (CGH) to identify specific chromosomal 
regions harboring loss or gain of DNA. Several investigators have documented 
recurrent loss of DNA at the 1p, 6q, 9p, and 13q chromosomal loci in parathyroid 
tumors, indicating the potential presence there of novel parathyroid tumor sup-
pressor genes [114–117]. The potential presence of novel oncogenes at chromosomal 
loci 9q, 16p, 19p, and Xq is suggested by results demonstrating specific chromo-
somal gain at these loci in benign or malignant parathyroid tumors [114, 116–118].
Next-generation sequencing analysis including WES of parathyroid neoplasms 
is an auspicious approach for the identification of novel acquired and germline gene 
variations that predispose to the development of HPT and parathyroid neoplasia. 
The apparent validation of this line of investigation by the identification of EXH2 
[36], ZFX [112], and potentially ASXL3 [108], as candidate driver genes for para-
thyroid neoplasia was previously discussed. WES analysis of parathyroid cancer-
derived DNA has similarly underscored the possible significance of recurrent 
somatic and germline inactivating mutations of PRUNE2 in the etiology of para-
thyroid malignancy [40]. The comprehensive quality and great sensitivity of WES 
and related next-generation sequencing methodologies should further advance 
our insight into the genetic basis and endocrine pathophysiology of inherited and 
sporadic parathyroid neoplasia in the decades ahead.
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